Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma-Reference-Cited by-同舟云学术

Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma

Published:2016-09 Issue: Volume:65 Page:182-184
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Kirchberger Michael C.,Hauschild Axel,Schuler Gerold,Heinzerling Lucie

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference6 articles.

1. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

2. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

3. Updated results from a phase III trial of nivolumab combined with ipilimumab in treatment-naïve patients with advanced melanoma (Checkmate 067), Chicago, Illinois;Wolchok,2016

4. Pembrolizumab + low-dose ipilimumab for advanced melanoma: results of the KEYNOTE-029 Expansion Cohort;Long,2016

5. KEYNOTE-029: pembrolizumab + low-dose ipilimumab for advanced melanoma;Long,2015

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody;Immunobiology;2024-11

2. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp;European Journal of Cancer;2023-09

3. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study;Journal for ImmunoTherapy of Cancer;2022-12

4. Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review;Current Oncology Reports;2022-04-07

5. Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure;Melanoma Research;2021-07-19